• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.通过受限平均生存时间进行两样本检验以分析事件时间观测值的效率
Biometrics. 2018 Jun;74(2):694-702. doi: 10.1111/biom.12770. Epub 2017 Sep 12.
2
Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.利用两个生存函数的综合差异来量化治疗对比,以用于设计、监测和分析比较性临床研究。
Clin Trials. 2012 Oct;9(5):570-7. doi: 10.1177/1740774512455464. Epub 2012 Aug 22.
3
A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.一项模拟研究比较了九种用于评估时间事件结局的随机对照试验中处理效应的检验效能。
Trials. 2020 Apr 6;21(1):315. doi: 10.1186/s13063-020-4153-2.
4
The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?平均风险比——当比例风险假设不成立时,用于事件发生时间终点的良好效应量度?
Methods Inf Med. 2018 May;57(3):89-100. doi: 10.3414/ME17-01-0058. Epub 2018 May 2.
5
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.使用受限平均生存时间替代风险比来解释癌症临床试验结果的可解释性。
JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797.
6
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.超越风险比:在生存分析中量化组间差异。
J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30.
7
Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.在可能预期治疗效果存在非比例风险的临床试验设计中增强对数秩检验。
BMC Med Res Methodol. 2016 Feb 11;16:16. doi: 10.1186/s12874-016-0110-x.
8
A comparison of different population-level summary measures for randomised trials with time-to-event outcomes, with a focus on non-inferiority trials.不同人群水平汇总指标在时间事件结局随机试验中的比较,重点关注非劣效性试验。
Clin Trials. 2023 Dec;20(6):594-602. doi: 10.1177/17407745231181907. Epub 2023 Jun 20.
9
A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves.一种基于Kaplan-Meier曲线加权差异的用于检验两个生存函数是否相等的通用方法。
Stat Med. 2015 Dec 10;34(28):3680-95. doi: 10.1002/sim.6591. Epub 2015 Jul 20.
10
Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy.平均风险与生存权重的比值和差值:量化新疗法生存获益的新指标。
Stat Med. 2023 Mar 30;42(7):936-952. doi: 10.1002/sim.9651. Epub 2023 Jan 5.

引用本文的文献

1
Summary measures in non-inferiority clinical trials with a time-to-event outcome: an empirical comparison of power.具有事件发生时间结局的非劣效性临床试验中的汇总指标:效能的实证比较
BMC Med Res Methodol. 2025 May 24;25(1):139. doi: 10.1186/s12874-025-02576-4.
2
Multi-group global tests for restricted mean survival time and restricted mean time lost: a variable transformation approach.受限平均生存时间和受限平均失能时间的多组全局检验:一种变量变换方法。
BMC Med Res Methodol. 2025 May 3;25(1):123. doi: 10.1186/s12874-025-02563-9.
3
Biomarker-guided adaptive enrichment design with threshold detection for clinical trials with time-to-event outcome.用于具有事件发生时间结局的临床试验的、具有阈值检测的生物标志物引导的适应性富集设计。
J Biopharm Stat. 2025 Apr 20:1-18. doi: 10.1080/10543406.2025.2489291.
4
On Sample Size Determination for Augmented Tests Based on Restricted Mean Survival Time in Randomized Clinical Trials.基于随机临床试验中受限平均生存时间的增强检验的样本量确定
Biom J. 2025 Apr;67(2):e70046. doi: 10.1002/bimj.70046.
5
Modeling the Restricted Mean Survival Time Using Pseudo-Value Random Forests.使用伪值随机森林对受限平均生存时间进行建模。
Stat Med. 2025 Feb 28;44(5):e70031. doi: 10.1002/sim.70031.
6
A Comparison of Statistical Methods for Time-To-Event Analyses in Randomized Controlled Trials Under Non-Proportional Hazards.非比例风险下随机对照试验中事件发生时间分析的统计方法比较
Stat Med. 2025 Feb 28;44(5):e70019. doi: 10.1002/sim.70019.
7
Power and Sample Size Calculations for the Restricted Mean Time Analysis of Prioritized Composite Endpoints.优先复合终点受限平均时间分析的效能与样本量计算
Stat Biopharm Res. 2023;15(3):540-548. doi: 10.1080/19466315.2022.2110936. Epub 2022 Oct 3.
8
Study design for restricted mean time analysis of recurrent events and death.限制平均时间分析复发性事件和死亡的研究设计。
Biometrics. 2023 Dec;79(4):3701-3714. doi: 10.1111/biom.13923. Epub 2023 Aug 23.
9
Dissecting the restricted mean time in favor of treatment.剖析有利于治疗的限定平均时间。
J Biopharm Stat. 2024 Jan 2;34(1):111-126. doi: 10.1080/10543406.2023.2210658. Epub 2023 May 24.
10
Omnibus test for restricted mean survival time based on influence function.基于影响函数的限制平均生存时间的综合检验。
Stat Methods Med Res. 2023 Jun;32(6):1082-1099. doi: 10.1177/09622802231158735. Epub 2023 Apr 4.

本文引用的文献

1
Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.肿瘤学随机对照试验中风险比和受限平均生存时间比测量的治疗效果比较。
J Clin Oncol. 2016 May 20;34(15):1813-9. doi: 10.1200/JCO.2015.64.2488. Epub 2016 Feb 16.
2
A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves.一种基于Kaplan-Meier曲线加权差异的用于检验两个生存函数是否相等的通用方法。
Stat Med. 2015 Dec 10;34(28):3680-95. doi: 10.1002/sim.6591. Epub 2015 Jul 20.
3
An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials.预防随机对照临床试验中几种风险替代方案的综合检验。
Stat Med. 2015 Feb 20;34(4):541-57. doi: 10.1002/sim.6366. Epub 2014 Nov 12.
4
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.超越风险比:在生存分析中量化组间差异。
J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30.
5
Predicting the restricted mean event time with the subject's baseline covariates in survival analysis.在生存分析中利用受试者的基线协变量预测受限平均事件时间。
Biostatistics. 2014 Apr;15(2):222-33. doi: 10.1093/biostatistics/kxt050. Epub 2013 Nov 29.
6
Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.利用两个生存函数的综合差异来量化治疗对比,以用于设计、监测和分析比较性临床研究。
Clin Trials. 2012 Oct;9(5):570-7. doi: 10.1177/1740774512455464. Epub 2012 Aug 22.
7
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.当存在比例风险假设的疑虑时,使用限制平均生存时间来估计随机临床试验中的治疗效果。
Stat Med. 2011 Aug 30;30(19):2409-21. doi: 10.1002/sim.4274. Epub 2011 May 25.
8
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.来那度胺联合高剂量地塞米松与来那度胺联合低剂量地塞米松作为初治多发性骨髓瘤的初始治疗:一项开放标签随机对照试验。
Lancet Oncol. 2010 Jan;11(1):29-37. doi: 10.1016/S1470-2045(09)70284-0. Epub 2009 Oct 21.
9
Improved logrank-type tests for survival data using adaptive weights.使用自适应权重对生存数据进行改进的对数秩检验。
Biometrics. 2010 Mar;66(1):30-8. doi: 10.1111/j.1541-0420.2009.01243.x. Epub 2009 Apr 13.
10
Power and sample size calculation for log-rank test with a time lag in treatment effect.具有治疗效果时间滞后的对数秩检验的功效和样本量计算。
Stat Med. 2009 Feb 28;28(5):864-79. doi: 10.1002/sim.3501.

通过受限平均生存时间进行两样本检验以分析事件时间观测值的效率

Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

作者信息

Tian Lu, Fu Haoda, Ruberg Stephen J, Uno Hajime, Wei Lee-Jen

机构信息

Department of Biomedical Data Science, Stanford University, California 94305, U.S.A.

Eli Lilly and Company, Indianapolis, Indiana 46285, U.S.A.

出版信息

Biometrics. 2018 Jun;74(2):694-702. doi: 10.1111/biom.12770. Epub 2017 Sep 12.

DOI:10.1111/biom.12770
PMID:28901017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5847424/
Abstract

In comparing two treatments with the event time observations, the hazard ratio (HR) estimate is routinely used to quantify the treatment difference. However, this model dependent estimate may be difficult to interpret clinically especially when the proportional hazards (PH) assumption is violated. An alternative estimation procedure for treatment efficacy based on the restricted means survival time or t-year mean survival time (t-MST) has been discussed extensively in the statistical and clinical literature. On the other hand, a statistical test via the HR or its asymptotically equivalent counterpart, the logrank test, is asymptotically distribution-free. In this article, we assess the relative efficiency of the hazard ratio and t-MST tests with respect to the statistical power under various PH and non-PH models theoretically and empirically. When the PH assumption is valid, the t-MST test performs almost as well as the HR test. For non-PH models, the t-MST test can substantially outperform its HR counterpart. On the other hand, the HR test can be powerful when the true difference of two survival functions is quite large at end but not the beginning of the study. Unfortunately, for this case, the HR estimate may not have a simple clinical interpretation for the treatment effect due to the violation of the PH assumption.

摘要

在比较两种具有事件时间观测值的治疗方法时,风险比(HR)估计值通常用于量化治疗差异。然而,这种依赖模型的估计值在临床上可能难以解释,尤其是当比例风险(PH)假设被违反时。基于受限平均生存时间或t年平均生存时间(t-MST)的治疗效果替代估计程序在统计和临床文献中已被广泛讨论。另一方面,通过HR或其渐近等效的对数秩检验进行的统计检验是渐近无分布的。在本文中,我们从理论和实证两方面评估了风险比检验和t-MST检验在各种PH和非PH模型下相对于统计功效的相对效率。当PH假设成立时,t-MST检验的表现几乎与HR检验一样好。对于非PH模型,t-MST检验的表现可能会大大优于HR检验。另一方面,当两种生存函数在研究结束时而非开始时的真实差异相当大时,HR检验可能会很有效。不幸的是,对于这种情况,由于PH假设被违反,HR估计值对于治疗效果可能没有简单的临床解释。